drugset / Trial / NCT03164291

Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex

NCT03164291

NaSingle-groupOpen-labelTreatment

Summary

Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections who have failed or are intolerant of rifampin. Rifabutin may be a reasonable alternative agent in patients who fail rifampin or or intolerant of rifampin.

Timeline

Start
1984-06
Primary completion
2006-09
Completion
2017-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifabutin Small molecule 150 mg
Subject Rifabutin Small molecule 300 mg